Glucagon Receptor

The glucagon receptor, GCGR, is a class B G protein-coupled receptor that responds to glucagon, a 29-amino-acid hormone secreted by pancreatic alpha-cells. Hepatocytes carry it at the highest density; kidney, fat tissue, heart and brain express less. Because glucagon and GLP-1 are both cut from proglucagon, their sequence similarity makes peptides that cross-react with several receptors chemically achievable.

Signalling as described in studies

Activated GCGR signals via Gs to adenylate cyclase and cAMP, stimulating glycogen breakdown and glucose production in the liver — the textbook counter-regulatory reaction when blood glucose drops. Apart from glucose release, rodent studies report more hepatic fatty-acid oxidation, higher energy expenditure and less fat stored in the liver, which is why metabolic research compounds deliberately include a glucagon component instead of steering clear of it.

Its role in multi-agonists

Combining GCGR activation with incretin activity is the concept underlying dual and triple agonists. Survodutide and mazdutide act at GCGR together with GLP-1; retatrutide also brings in GIP. The balance explored in the literature is that glucagon acting alone pushes glucose up, so the incretin component must offset it — these molecules are defined by their receptor potency ratios, not merely by how many receptors they hit.

Related terms

GIP · incretin. See the glucagon research family, Survodutide, Retatrutide, and Survodutide vs Mazdutide.